Interferon-lambda: New role in intestinal symptoms of COVID-19

doi:10.3748/wjg.v29.i13.1942

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 13

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7691)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

319

WORD

HTML

3787

Figures (1-2)

759

Sum=4908

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

280

Download

1019

Sum=1299

Publishing Process of This Article

Item

Count

Browse

410

Download

1069

Sum=1479

Apr 7, 2023 (publication date) through Feb 20, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Apr 7, 2023; 29(13): 1942-1954
Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.1942

Interferon-lambda: New role in intestinal symptoms of COVID-19

Yi-Yang Pan, Liu-Can Wang, Feng Yang, Min Yu

Yi-Yang Pan, Liu-Can Wang, Feng Yang, Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing 400037, China

Min Yu, Department of General Surgery, Chongqing General Hospital, Chongqing 400013, China

Author contributions: Pan YY wrote the manuscript; Pan YY and Wang LC draw the pictures; Yang F collated the data; Yu M and Pan YY revised the manuscript.

Supported by National Natural Science Foundation of China (to M.Y.), No. 81970468.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Min Yu, PhD, Professor, Department of General Surgery, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New District, Chongqing 400013, Chongqing, China. yumimianbao@163.com

Received: November 29, 2022
Peer-review started: November 29, 2022
First decision: December 19, 2022
Revised: December 25, 2022
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 7, 2023
Processing time: 128 Days and 20 Hours

Core Tip

Core Tip: The tremendous public health and economic impact of the coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a huge challenge for countries across the whole world. Increased evidences have revealed that SARS-CoV-2 also induced intestinal infection. Type III interferon (IFN), also called IFN-λ, plays an antiviral role in intestinal infection, and has focused, long-lasting, as well as non-inflammatory characteristics. In this review, we summarized the invasion and immune escape mechanisms of the SARS-CoV-2. Furthermore, we concerned about the gastrointestinal impact of the SARS-CoV-2 and the comprehensive role of IFN-λ, also called type III IFN, in anti-enteric SARS-CoV-2 infection.